log in
Print | Back

Haynes and Boone, LLP

Michelle Missy D Apodaca

Michelle Missy D Apodaca

Haynes and Boone, LLP
Texas, U.S.A.

tel: +1 512 867 8427
Send an Email

Local Time: Tue. 06:56

Healthcare providers benefit from Michelle Apodaca’s unique blend of business and legal experience, her comprehensive understanding of healthcare legislative policy and regulation, and her unwavering enthusiasm to assist clients address the challenges they face with day-to-day operations as well as long-term objectives and strategic alignment. Hospitals and health systems, physician practices, and healthcare payors rely on Michelle’s insight into operational, business and related regulatory issues including alignment of incentives and business strategies in the post Affordable Care Act health care marketplace; assisting in the transition from fee-for-service to quality/value based payments; implementing and maintaining quality initiatives and developing and leading state legislative and regulatory policy agendas with the Texas Legislature, Texas Health and Human Services Commission, Texas Department of State Health Services, Texas Department of Insurance, Texas Medical Board, Texas Dental Board, and Texas Pharmacy Board.

Prior to entering private practice, Michelle served the Texas Hospital Association members as the vice president of advocacy, legal and public policy. Earlier in her career she served as in-house legal counsel and compliance officer for a Texas health maintenance organization and as a legislative aide in both the Texas State Senate and the U.S. House of Representatives. The breadth and depth of her experience underscore Michelle's zealous advocacy for clients who depend on her advice to plan proactively for the evolving healthcare landscape. Michelle’s understanding of policy and politics enables her to assist clients participating in state-managed Medicaid programs, the Children's Health Insurance Program (CHIP) and the Medicare Advantage program. Michelle also assists clients with the licensure of healthcare collaborative organizations and ACOs, HMOs, third-party administrators, discount healthcare programs, acute care hospitals, Texas non-profit health corporations (5.01a’s) and behavioral healthcare facilities and units. Providers consult Michelle on securing Medicare provider-based status and federally qualified health center/look-alike funding. She also develops public policy, advocacy and regulatory affairs programs at the federal and state levels for healthcare providers.

Michelle’s legislative and regulatory areas of experience include:

1115 Medicaid Transformation Waiver
Contracting with state agencies
Health insurance policy (commercial, Medicare, Medicare Advantage, Medicaid, Medicaid managed care, STAR+PLUS and CHIP)
Modifying the Texas Pharmacy Act
Dental service organizations
Texas Dual Eligible Integrated Care project
Health care facility and provider licensure
State specific designations impacting reimbursements

Michelle is a frequent and respected speaker on the Texas Medicaid program and the impact of the Affordable Care Act on health care providers. She has spoken at numerous regional and national health law and trade association conferences, and from 2012-2014 she co-chaired the program planning committee for the ABA Health Law Section’s Annual Washington Health Law Summit.


J.D., Texas A&M University School of Law (formerly Texas Wesleyan University School of Law), 1998
B.A., Business Administration, Austin College, 1989
Areas of Practice

Health Law Vitals - A Healthcare Newsletter from Haynes and Boone, March 2018
Haynes and Boone, LLP, March 2018

 More than two and a half years after the U.S. Food and Drug Administration (FDA) announced that it was reevaluating its regulatory framework for homeopathic products, the FDA released its Draft Guidance on Drug Products Labeled as Homeopathic. The Draft Guidance summarizes the FDA’s current enforcement perspective on homeopathic products and provides a list of the FDA’s enforcement priorities.The bills reawakened a debate about the pros and cons of POHs...

Health Law Vitals - A Healthcare Newsletter from Haynes and Boone, November 2017
Haynes and Boone, LLP, November 2017

View a PDF of the November 2017 edition of the Haynes and Boone Health Law Vitals newsletter. FDA Improving Regulatory Oversight of Stem Cell Therapies and Regenerative Medicine Products Regenerative medicine is a burgeoning interdisciplinary research field aiming to offer new therapies that replace or regenerate human cells, tissues, or organs with the goal of restoring or establishing normal function...

Health Law Vitals - A Healthcare Newsletter from Haynes and Boone, February 2017
Haynes and Boone, LLP, February 2017

  View the February 2017 Health Law Vitals Newsletter PDF. Final Guidance Sheds Light on Medical Device Reporting Requirements In November 2016, the U.S. Food and Drug Administration issued a final guidance on medical device reporting for manufacturers ("Final MDR Guidance")...

WSG's members are independent firms and are not affiliated in the joint practice of professional services. Each member exercises its own individual judgments on all client matters.

HOME | SITE MAP | GLANCE | DISCLAIMER |  © World Services Group, 2018